Story

Jazz Pharmaceuticals Stock Hits Record High on FDA Approval for Cancer Drug Ziihera

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
Jazz Pharmaceuticals Stock Hits Record High on FDA Approval for Cancer Drug Ziihera
Text size
Background

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) climbed 2.3% in afternoon trading Tuesday, reaching a new all-time high after the U.S. Food and Drug Administration (FDA) approved its cancer therapy, Ziihera (zanidatamab-hrii).

FDA Greenlights New Cancer Therapy

The FDA granted approval for two Ziihera-containing combination regimens as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of stomach or esophageal cancer. The agency's decision arrived on its PDUFA (Prescription Drug User Fee Act) target action date of August 25, 2026.

The approval covers two distinct treatment approaches:

  • A triplet regimen of Ziihera combined with Tevimbra (tislelizumab-jsgr) and chemotherapy.
  • A doublet regimen of Ziihera combined with chemotherapy alone.

Market Reaction and Outlook

Sample IUX Markets – In-articleAd

The positive regulatory news acted as a significant catalyst for the stock, pushing it to an intraday and all-time high of $266.38. The approval reinforces growing investor confidence, which had been building following a strong second-quarter 2026 earnings report where Jazz posted revenue of $1.21 billion, surpassing consensus estimates.

Analyst sentiment has been positive, with multiple Wall Street firms raising their price targets on the company ahead of the decision. Current price targets from major analysts range from $264 to $310, reflecting optimism about the company's diversified neuroscience and oncology pipeline.

Broader Context

The approval also had a positive impact on Jazz's partners, including BeOne Medicines and Zymeworks, the originator of the zanidatamab molecule. The broader market provided a modest tailwind, with the S&P 500 up approximately 0.3% on the day.

Overall, the combination of a significant and long-awaited FDA approval, a strong recent financial performance, and supportive analyst ratings converged to drive the stock to record levels, underscoring the market's validation of Jazz Pharmaceuticals' oncology growth strategy.

Read next

More on Stocks
Back to latest news

LATEST